Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Poll|October 1, 2020
Mini Quiz: Cognitive Enhancers
Which pharmacotherapeutic approach is most effective for cognitive enhancement? Test your knowledge with this quiz.
Advertisement
While not considered first line, which of the following pharmacotherapeutic approaches has the most evidence for effectiveness in cognitive enhancement at present?
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
Check out our pipeline updates from September!
Don't miss out on these CME articles! Test your knowledge here.
A cross-sector ACNP task force calls for shared standards and shared data to move psychiatry beyond trial-and-error prescribing.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Advertisement
Advertisement